From professional translators, enterprises, web pages and freely available translation repositories.
metabolisers:
korral:
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
poor metabolisers
aeglased metaboliseerijad
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
cyp2c19 poor metabolisers
cyp2c19 nõrgad metaboliseerijad
Last Update: 2012-04-11
Usage Frequency: 3
Quality:
in poor metabolisers (pms):
madala ensümaatilise aktiivsusega patsiendid
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
known cyp2d6 poor metabolisers
cyp2d6 aeglased metaboliseerijad
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
interactions in cyp2d6 poor metabolisers
koostoimed cyp2d6 aeglastel metaboliseerijatel
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
expected in cyp2c19 poor metabolisers:
eeldatav cyp2c19 halbade metaboliseerijate
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
in intermediate (ims) and extensive metabolisers (ems):
keskmine ja kõrge ensümaatiline aktiivsus:
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
for caucasians and blacks the prevalence of poor metabolisers is 35%.
Üldkasutatavates farmakoloogilise ohutuse, genotoksilisuse ja kartsinogeensuse uuringutes ei täheldatud inimesele erilist ohtu.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
cyp2d6 ultra-rapid metabolisers (urms) and indeterminate metabolisers
cyp2d6 ülikõrge ja määratlemata aktiivsusega isikud
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
no dose adjustment is necessary in patients known to be cyp2c9 poor metabolisers.
cyp2c9 aeglaselt metaboliseerivatel patsientidel ei ole vaja annust muuta.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
for caucasians and blacks the prevalence of poor metabolisers is 3-5 %.
nimetatud ensüümile on iseloomulik geneetiline polümorfism.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
in subjects who are poor metabolisers, darifenacin exposure increased approximately 10-fold.
aeglastel metaboliseerijatel suurenes darifenatsiini ekspositsioon ligikaudu 10 korda.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
the effects of desloratadine in poor metabolisers < 2 years of age have not been studied.
desloratadiini toimet nõrga metabolisatsiooniga < 2-aastastel ei ole uuritud.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Warning: Contains invisible HTML formatting
eliglustat is also contraindicated in patients who are cyp2d6 poor metabolisers taking a strong cyp3a inhibitor.
eliglustaat on samuti vastunäidustatud patsientidele, kelle cyp2d6 aktiivsus on madal, ja kes võtavad cyp3a tugevat inhibiitorit.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
for example, 15-20% of asian populations may be expected to be poor metabolisers.
rottidel, hiirtel ja koertel kutsus vorikonasool esile ka minimaalsed muutused neerupealistes.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
however, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolisers of cyp2d6 substrates.
cyp2d6 substraatide halbade ja ulatuslike metaboliseerijate kliinilise farmakokineetika parameetrid ei ole aga oluliselt erinevad.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
oral dosing of 84 mg eliglustat once daily has not been studied in cyp2d6 poor metabolisers (pms).
cyp2d6 madala aktiivsusega isikutel ei ole uuritud eliglustaadi 84 mg üks kord ööpäevas suukaudu manustatavat annust.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
16 applies to subjects who have normal cyp2d6 activity (extensive metabolisers) unless otherwise stated.
alltoodud informatsioon kehtib cyp2d6 normaalse aktiivsusega isikute kohta (kiired metaboliseerijad), kui ei ole märgitud teisiti.
Last Update: 2012-04-11
Usage Frequency: 4
Quality:
clinical experience in cyp2d6 poor metabolisers (pms) and ultra-rapid metabolisers (urms)
kliiniline kogemus cyp2d6 madala ja ülikõrge ensümaatilise aktiivsusega patsientidel
Last Update: 2017-04-26
Usage Frequency: 1
Quality: